Every 8-K that DALRADA TECHNOLOGY GROUP (DHTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DHTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DHTI filings page.
Dalrada Technology Group, Inc. reported that it and certain subsidiaries received a notice of default on multiple credit facilities from Nautilus entities on April 24, 2026. The lender cites missed required payments and is demanding a $500,000 cure payment by May 1, 2026.
If the cure is not made, the lender may accelerate the loan balances and begin enforcement actions under the term loan and factoring agreements. Dalrada is reviewing the notice and plans to discuss potential resolutions, but states there is no assurance the defaults will be cured or that acceleration and enforcement will be avoided.
Dalrada Technology Group, through its subsidiary Genefic Inc., amended a prior report to clarify that new financing agreements create up to $25,000,000 in aggregate commitments, not $20,000,000 as first disclosed. The package combines up to $20,000,000 of standby letters of credit and related guarantees with a linked $5,000,000 revolving accounts receivable facility supporting Genefic’s healthcare operations.
The facilities run from December 31, 2025 to December 31, 2030 and are secured by first-priority liens on substantially all assets of Genefic and the parent company, plus a pledge of 100% of equity in all subsidiaries. Chairman and CEO Brian Bonar has provided an unlimited personal guaranty that is joint and several with the company’s obligations, and the board highlights resulting conflicts of interest between his personal exposure and his duties to shareholders. Upfront consideration includes $140,000 in cash, a $165,000 promissory note, and a pre-funded warrant valued at $225,000.
Dalrada Technology Group, through its wholly owned subsidiary Genefic Inc., entered into a financing structure providing up to $20,000,000 in guarantees and related credit support with IBS-affiliated funds. A related receivables-based revolving facility may provide up to $5,000,000 in funding for Genefic’s healthcare operations.
The arrangements are secured by first-priority liens on substantially all assets of Genefic and a first-priority security interest in substantially all assets of Dalrada, plus a pledge of 100% of the equity in all Dalrada subsidiaries. CEO Brian Bonar also provided an unlimited personal guaranty of Genefic’s obligations, which the Board identified as creating multiple potential conflicts of interest. Dalrada did not receive separate consideration for its upstream guarantee beyond benefits to Genefic.
Dalrada Technology Group, Inc. filed a current report to share that its Chief Executive Officer and Chairman, Brian Bonar, issued an open letter to shareholders dated January 20, 2026. The letter reviews the company’s 2025 performance, discusses operational progress in its core markets of renewable energy and heat pumps, atmospheric water generators, and semiconductor deposition solutions, and highlights recent partnerships, installations, and restructuring efforts. It also outlines Dalrada’s strategic focus and outlook for 2026 and beyond. The letter is included as Exhibit 99.1 and is furnished, rather than filed, under the securities laws.